Why the study?
Does low-dose methotrexate reduce the rate of cardiovascular events in coronary patients with either type 2 diabetes or metabolic syndrome?
Does low-dose methotrexate reduce the rate of cardiovascular events in coronary patients with either type 2 diabetes or metabolic syndrome?
No takes yet. Share an insight, caveat, or question.
This editorial discusses the rationale for the CIRT trial, which evaluates whether inhibiting inflammation with low-dose methotrexate reduces cardiovascular events in high-risk coronary patients.
Reiner et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: